The Business Times

Abbott wins EU approval for smallest version of glucose monitoring device

Published Mon, Sep 28, 2020 · 01:33 PM

[BENGALURU] Abbott Laboratories' said on Monday it had received clearance to market the smallest version of its fastest-growing low-cost diabetes monitoring product in the European Union.

FreeStyle Libre 3, which received the European CE Mark, is a more discreet sensor and will be priced the same as previous versions of the device, the company said.

The earlier version, Libre 2, is priced at US$54, while a handheld reader, used to scan the sensor, is available for a one-time cost of US$70.

FreeStyle Libre 3 is a continuous glucose monitoring device that allows diabetics to track their blood sugar levels without multiple daily finger sticks.

Patients using the new version will also be able to receive glucose readings automatically on their smartphones through the FreeStyle Libre 3 mobile app.

The Libre 3 sensor, like other versions, is worn at the back of the upper arm for 14 days.

GET BT IN YOUR INBOX DAILY

Start and end each day with the latest news stories and analyses delivered straight to your inbox.

VIEW ALL

In April, the company said worldwide sales of Freestyle Libre devices rose 59.3 per cent to US$600 million in the first quarter of 2020.

REUTERS

KEYWORDS IN THIS ARTICLE

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to  t.me/BizTimes

Consumer & Healthcare

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

Get the latest coverage and full access to all BT premium content.

SUBSCRIBE NOW

Browse corporate subscription here